YAHOO FINANCE CHARTBOOK

44 charts that explain markets and the economy right now

Frankfurt - Delayed Quote EUR

Ono Pharmaceutical Co., Ltd. (ON4.F)

10.20

+0.30

+(3.03%)

At close: January 28 at 3:29:02 PM GMT+1

ONO Enters into a Definitive Agreement to Acquire Deciphera Pharmaceuticals

ONO Pharmaceutical, Co., Ltd., (TSE: 4528, Representative Director, Chairman of the Board and Chief Executive Officer: Gyo Sagara, "ONO") and Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH, Chief Executive Officer: Steven L. Hoerter, "Deciphera") today announced that on April 29, 2024 (Japan time), ONO and Deciphera entered into a definitive merger agreement under which ONO will acquire all outstanding shares of Deciphera common stock for US $ 25.60 per share in cash through a tender offer follow

PR Newswire 8 months ago

OPHLF

OPHLY
0.00%
Japan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansion

Japan's Ono Pharmaceutical Co said on Tuesday its $2.4 billion takeover of Deciphera Pharmaceuticals is a "first step" in expanding in U.S. and European markets. With this deal, Ono Pharma joins Japanese rivals Takeda Pharmaceutical and Astellas Pharma which have spent big recently to replenish their drug pipelines. Ono Pharma is best known globally for its blockbuster cancer drug Opdivo, which is sold in the U.S. by partner Bristol-Myers Squibb.

Reuters 8 months ago

OPHLY
0.00%
DCPH
Deciphera Catapults 73% On Ono Pharmaceutical's $2.4 Billion Takeover

Deciphera stock rocketed to a three-year high Monday after Ono Pharmaceutical agreed to buy it for $2.4 billion.

Investor's Business Daily 8 months ago

OPHLY
0.00%
Ono Pharmaceutical acquires cancer-focused biopharma Deciphera for $2.4bn

Ono will gain access to Deciphera’s kinase inhibitor pipeline, which includes the CSF-1 inhibitor vimseltinib and ULK inhibitor DCC-3116.

Pharmaceutical Technology 8 months ago

OPHLY
0.00%
DCPH

GLDAF
Deciphera to sell for $2.4B, adding to upswing in biopharma M&A

For Japan-based Ono Pharmaceutical, buying Deciphera offers a way to build out in cancer research as well as get a stronger foothold in the U.S. and European markets.

BioPharma Dive 8 months ago

OPHLY
0.00%
DCPH
UPDATE 2-Japan's Ono to buy US drugmaker Deciphera for $2.4 bln

Deciphera Pharmaceuticals said on Monday Japan's Ono Pharmaceutical Co will acquire the cancer drugmaker for $2.4 billion to expand its oncology portfolio and presence in the United States and Europe. Ono Pharma has offered $25.60 per share in cash, a premium of 74.7% to U.S.-based Deciphera's last closing price of $14.65. Some shareholders who own about 28% of Deciphera's outstanding stock have already agreed to tender their shares and support the deal, which is expected to close in the third quarter of 2024, the company said.

Reuters 8 months ago

OPHLY
0.00%
DCPH
Q4 2023 Cue Biopharma Inc Earnings Call

Q4 2023 Cue Biopharma Inc Earnings Call

Thomson Reuters StreetEvents 9 months ago

CUE

OPHLY
0.00%
Fate Therapeutics Inc (FATE) Reports Fourth Quarter and Full Year 2023 Financial Results

Advancements in Clinical Trials and Strong Cash Position Highlighted

GuruFocus.com 10 months ago

FATE

OPHLY
0.00%

Performance Overview

Return	ON4.F	Nikkei 225
YTD	+5.70%	-1.69%
1-Year	-83.81%	+8.86%
3-Year	+16.38%	+46.80%